Antibody-drug conjugates in oncology: From the concept to trastuzumab emtansine (T-DM1);Lesanticorps conjugués en oncologie: Du concept au trastuzumab emtansine (T-DM1)

Bulletin du Cancer

Volumn 99, Issue 12, 2012, Pages 1183-1191

  Gonçalves, Anthony ^a,b   Trédan, Olivier ^c,d   Villanueva, Christian ^e   Dumontet, Charles ^d  

^a INSTITUT PAOLI CALMETTES   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c CENTRE LÉON BÉRARD   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

^e UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

Clinical benefit; HER2 positive breast cancer; Objective response; Safety; Trastuzumab emtansine

Indexed keywords

CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB; TAXANE DERIVATIVE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; IMMUNOTOXIN; MAYTANSINE; MONOCLONAL ANTIBODY; TRASTUZUMAB DM1 CONJUGATE; TRASTUZUMAB-DM1 CONJUGATE;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; DRUG CONJUGATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; REVIEW; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DRUG SCREENING; FEMALE;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; FEMALE; HUMANS; IMMUNOTOXINS; MAYTANSINE;

MLCS; MLOWN;

EID: 84872361695     PISSN: 00074551     EISSN: 17696917     Source Type: Journal    
DOI: 10.1684/bdc.2012.1669     Document Type: Article

References (41)

1. Dawood S, Broglio K, Buzdar AU, et al. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 2010; 28 : 92-8.
2. Johnson JR, Ford CH, Newman CE, et al. A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro. Br J Cancer 1981; 44 : 472-5. (Pubitemid 11007291)
3. Garnett MC. Targeted drug conjugates: principles and progress. Adv Drug Deliv Rev 2001; 53 : 171-216. (Pubitemid 33135563)
4. Maxfield FR, McGraw TE. Endocytic recycling. Nat Rev Mol Cell Biol 2004; 5 : 121-32. (Pubitemid 38160255)
5. Bross PF, Beitz J, Chen G, et al. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res 2001; 7 : 1490-6. (Pubitemid 32708610)
6. Sievers EL, Linenberger M. Mylotarg: antibody-targeted chemotherapy comes of age. Curr Opin Oncol 2001; 13 : 522-7. (Pubitemid 33027906)
7. FDA.Gov. Mylotarg (gemtuzumab ozogamicin): market withdrawal, 2010, Disponible sur : http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm216458.htm?utm-campaign= Google2&utm-source=fdaSearch&utm-medium=website&utm-term= ucm216458&utm-content=1.
8. Katz J, Janik JE, Younes A. Brentuximab Vedotin (SGN-35). Clin Cancer Res 2011; 17 : 6428-36.
9. Chamarthy MR, Williams SC, Moadel RM. Radioimmunotherapy of non-Hodgkin's lymphoma: from the "magic bullets" to "radioactive magic bullets". Yale J Biol Med 2011; 84 : 391-407.
10. Burris 3rd. HA, Tibbitts J, Holden SN, et al. Trastuzumab emtansine (T-DM1): a novel agent for targeting HER2 + breast cancer. Clin Breast Cancer 2011; 11 : 275-82.
11. Albanell J, Codony J, Rovira A, et al. Mechanism of action of anti-HER2 monoclonal antibodies: scientific update on trastuzumab and 2C4. Adv Exp Med Biol 2003; 532 : 253-68. (Pubitemid 37176793)
12. Lewis GD, Figari I, Fendly B, et al. Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies. Cancer Immunol Immunother 1993; 37 : 255-63. (Pubitemid 23300507)
13. Cooley S, Burns LJ, Repka T, et al. Natural killer cell cytotoxicity of breast cancer targets is enhanced by two distinct mechanisms of antibody-dependent cellular cytotoxicity against LFA-3 and HER2/neu. Exp Hematol 1999; 27 : 1533-41. (Pubitemid 29458428)
14. Clynes RA, Towers TL, Presta LG, et al. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6 : 443-6. (Pubitemid 30208162)
15. Molina MA, Codony-Servat J, Albanell J, et al. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61 : 4744-9. (Pubitemid 32691885)
16. Lewis Phillips GD, Li G, Dugger DL, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 2008; 68 : 9280-90.
17. Dumontet C. Antitubulin agents. Bull Cancer 2011; 98 : 1275-85.
18. Baselga J, Norton L, Albanell J, et al. Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58 : 2825-31. (Pubitemid 28311914)
19. Pegram M, Hsu S, Lewis G, et al. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 1999; 18 : 2241-51. (Pubitemid 29186925)
20. Konecny GE, Thomssen C, Luck HJ, et al. Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer. J Natl Cancer Inst 2004; 96 : 1141-51. (Pubitemid 39207050)
21. Burstein HJ, Keshaviah A, Baron AD, et al. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007; 110 : 965-72. (Pubitemid 47312860)
22. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5 : 147-59.
23. Erickson HK, Park PU, Widdison WC, et al. Antibody-maytansinoid conjugates are activated in targeted cancer cells by lysosomal degradation and linker-dependent intracellular processing. Cancer Res 2006; 66 : 4426-33.
24. Austin CD, De Maziere AM, Pisacane PI, et al. Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin. Mol Biol Cell 2004; 15 : 5268-82. (Pubitemid 39564723)
25. Barok M, Tanner M, Köninki K, Isola J. Trastuzumab-DM1 causes tumour growth inhibition by mitotic catastrophe in trastuzumabresistant breast cancer cells in vivo. Breast Cancer Res 2011; 13 : R46.
26. Junttila TT, Li G, Parsons K, et al. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat 2011; 128 : 347-56.
27. Lewis Phillips GD. Potent anti-tumor activity of trastuzumab-DM1 antibodydrug conjugate in combination with cytotoxic chemotherapeutic agents, antibodies or small molecule kinase inhibitors. In : 99th AACR Annual Meeting, 2008.
28. Fields CT, Crocker LM, Sliwkowski MX, et al. Dual targeting of HER2: enhanced anti-tumor efficacy of trastuzumab-dm1 combined with pertuzumab. In : AACR-EORTC, 2010.
29. Krop IE, Beeram M, Modi S, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28 : 2698-704.
30. Holden SN. A phase I study of weekly dosing of trastuzumab-DM1 (T-DM1) in patients (pts) with advanced HER2+ breast cancer (BC). In : ASCO Annual Meeting, 2008.
31. Burris 3rd. HA, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29 : 398-405.
32. Krop IE, LoRusso P, Modi S, et al. A Phase II study of trastuzumab-DM1 (T-DM1), a novel HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer who were previously treated with an anthracycline, a taxane, capecitabine, lapatinib, and trastuzumab. In : San Antonio breast cancer symposium SABCS, 2009.
33. Krop IE, LoRusso P, Miller KD, et al. A phase 2 study of the HER2 antibody-drug conjugate trastuzumab-DM1 (T-DM1) in patients with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. In : European Society for Medical Oncology (ESMO), 2010.
34. Perez EA, Dirix L, Kocsis J, et al. Efficacy and safety of trastuzumab-DM1 versus trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase II study (TDM4450g). In : European Society for Medical Oncology (ESMO), 2010.
35. Baselga J, Gelmon KA, Verma S, et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010; 28 : 1138-44.
36. Miller K, Gianni L, André F, et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC)who were previously treated with trastuzumab (T). In : ASCO, 2010.
37. Dieras V, Harbeck N, Albain K, et al. A phase Ib/II Trial of trastuzumab-DM1 (T-DM1) with pertuzumab for patients with HER2-Positive, locally advanced or metastatic breast cancer: interim efficacy and safety results. In : San Antonio Breast Cancer Symposium, 2010.
38. Perez EA, Koehler M, Byrne, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83 : 679-86.
39. Chien AJ, Rugo HS. The cardiac safety of trastuzumab in the treatment of breast cancer. Expert Opin Drug Saf 2010; 9 : 335-46.
40. Blackwell KL, Miles D, Gianni L, et al. Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane. In : 2012 ASCO Annual Meeting, 2012.
41. Verma S, Miles D, Gianni L, et al. Trastuzumab emtansine for her2-positive advanced breast cancer. N Engl J Med 2012; 367 : 1783-91.